Jeffrey Bolton Buys 10,000 Shares of Enhabit, Inc. (NYSE:EHAB) Stock

Enhabit, Inc. (NYSE:EHABGet Free Report) Director Jeffrey Bolton acquired 10,000 shares of the company’s stock in a transaction that occurred on Friday, May 17th. The shares were acquired at an average cost of $8.33 per share, with a total value of $83,300.00. Following the purchase, the director now owns 52,299 shares in the company, valued at approximately $435,650.67. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Jeffrey Bolton also recently made the following trade(s):

  • On Friday, May 10th, Jeffrey Bolton bought 10,000 shares of Enhabit stock. The shares were bought at an average price of $8.24 per share, for a total transaction of $82,400.00.

Enhabit Stock Down 1.2 %

Shares of EHAB opened at $8.25 on Friday. The company’s 50-day moving average price is $10.34 and its 200 day moving average price is $10.07. Enhabit, Inc. has a 12-month low of $7.12 and a 12-month high of $14.59. The company has a debt-to-equity ratio of 0.75, a quick ratio of 1.50 and a current ratio of 1.50.

Enhabit (NYSE:EHABGet Free Report) last released its quarterly earnings results on Wednesday, March 6th. The company reported $0.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.02 by $0.01. The business had revenue of $260.60 million for the quarter, compared to the consensus estimate of $260.30 million. Enhabit had a negative net margin of 7.95% and a positive return on equity of 1.43%. During the same period in the previous year, the firm earned $0.32 EPS. Equities research analysts expect that Enhabit, Inc. will post 0.24 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on EHAB shares. UBS Group upgraded Enhabit from a “sell” rating to a “neutral” rating and set a $9.50 price objective on the stock in a research report on Thursday, March 7th. Oppenheimer reissued a “market perform” rating on shares of Enhabit in a research report on Thursday, March 7th. SVB Leerink raised shares of Enhabit from an “underperform” rating to a “market perform” rating and set a $8.50 price objective for the company in a report on Tuesday, May 14th. Jefferies Financial Group downgraded shares of Enhabit from a “buy” rating to a “hold” rating and reduced their target price for the stock from $14.00 to $8.75 in a research note on Thursday, May 9th. Finally, Leerink Partnrs raised shares of Enhabit from a “strong sell” rating to a “hold” rating in a research note on Tuesday, May 14th. One equities research analyst has rated the stock with a sell rating and seven have issued a hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $10.13.

Read Our Latest Report on Enhabit

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. DekaBank Deutsche Girozentrale boosted its stake in shares of Enhabit by 12,146.2% in the fourth quarter. DekaBank Deutsche Girozentrale now owns 244,924 shares of the company’s stock valued at $2,543,000 after purchasing an additional 242,924 shares during the period. Ancora Advisors LLC lifted its holdings in Enhabit by 414.5% during the 3rd quarter. Ancora Advisors LLC now owns 1,705,788 shares of the company’s stock worth $19,190,000 after buying an additional 1,374,231 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its position in Enhabit by 26.3% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 772,840 shares of the company’s stock valued at $8,694,000 after buying an additional 160,776 shares during the period. JANA Partners Management LP acquired a new position in shares of Enhabit in the third quarter worth $20,532,000. Finally, CenterBook Partners LP increased its position in shares of Enhabit by 88.7% during the third quarter. CenterBook Partners LP now owns 301,418 shares of the company’s stock worth $3,391,000 after acquiring an additional 141,718 shares during the period.

Enhabit Company Profile

(Get Free Report)

Enhabit, Inc provides home health and hospice services in the United States. Its home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery, or injury and respiratory diseases; and physical, occupational and speech therapists provide therapy services.

See Also

Receive News & Ratings for Enhabit Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enhabit and related companies with's FREE daily email newsletter.